ArticleOncoTargets and therapy2021

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.

Ling Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.